Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies.

American journal of clinical and experimental urology

Armstrong CM, Gao AC.
PMID: 26309896
Am J Clin Exp Urol. 2015 Aug 08;3(2):64-76. eCollection 2015.

Several mechanisms facilitate the progression of hormone-sensitive prostate cancer to castration-resistant prostate cancer (CRPC). At present, the approved chemotherapies for CRPC include systemic drugs (docetaxel and cabazitaxel) and agents that target androgen signaling, including enzalutamide and abiraterone. While up...

Cite
Armstrong CM, Gao AC. Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. Am J Clin Exp Urol. 2015;3(2):64-76
Armstrong, C. M., & Gao, A. C. (2015). Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. American journal of clinical and experimental urology, 3(2), 64-76.
Armstrong, Cameron M, and Gao, Allen C. "Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies." American journal of clinical and experimental urology vol. 3,2 (2015): 64-76.
Armstrong CM, Gao AC. Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. Am J Clin Exp Urol. 2015 Aug 08;3(2):64-76. eCollection 2015. PMID: 26309896; PMCID: PMC4539108.
Copy Download .nbib Format: NLM
Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer.

Translational oncology

Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Chen H, Dall'Era M, Ghosh PM, Evans CP, Gao AC.
PMID: 31075528
Transl Oncol. 2019 Jul;12(7):871-878. doi: 10.1016/j.tranon.2019.04.007. Epub 2019 May 07.

Castration-resistant prostate cancer remains as an incurable disease. Exploiting DNA damage repair defects via inhibition of poly (ADP-ribose) polymerase (PARP) is becoming an attractive therapeutic option. The TOPARP-A clinical trial demonstrated that the PARP inhibitor olaparib may be an...

Cite
Lombard AP, Liu C, Armstrong CM, et al. Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. Transl Oncol. 2019;12(7):871-878doi: 10.1016/j.tranon.2019.04.007.
Lombard, A. P., Liu, C., Armstrong, C. M., D'Abronzo, L. S., Lou, W., Chen, H., Dall'Era, M., Ghosh, P. M., Evans, C. P., & Gao, A. C. (2019). Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. Translational oncology, 12(7), 871-878. https://doi.org/10.1016/j.tranon.2019.04.007
Lombard, Alan P, et al. "Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer." Translational oncology vol. 12,7 (2019): 871-878. doi: https://doi.org/10.1016/j.tranon.2019.04.007
Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Chen H, Dall'Era M, Ghosh PM, Evans CP, Gao AC. Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. Transl Oncol. 2019 Jul;12(7):871-878. doi: 10.1016/j.tranon.2019.04.007. Epub 2019 May 07. PMID: 31075528; PMCID: PMC6510951.
Copy Download .nbib Format: NLM
Resistance Mechanisms to Taxanes and PARP Inhibitors in Advanced Prostate Cancer.

Current opinion in endocrine and metabolic research

Lombard AP, Gao AC.
PMID: 32258820
Curr Opin Endocr Metab Res. 2020 Feb;10:16-22. doi: 10.1016/j.coemr.2020.02.006. Epub 2020 Feb 19.

The clinical landscape concerning advanced prostate cancer is rapidly changing and reaching beyond androgen deprivation therapy and androgen receptor targeted therapies. Taxane chemotherapy is a critical tool in the management of advanced prostate cancer. Additionally, novel drug classes such...

Cite
Lombard AP, Gao AC. Resistance Mechanisms to Taxanes and PARP Inhibitors in Advanced Prostate Cancer. Curr Opin Endocr Metab Res. 2020;10:16-22doi: 10.1016/j.coemr.2020.02.006.
Lombard, A. P., & Gao, A. C. (2020). Resistance Mechanisms to Taxanes and PARP Inhibitors in Advanced Prostate Cancer. Current opinion in endocrine and metabolic research, 1016-22. https://doi.org/10.1016/j.coemr.2020.02.006
Lombard, Alan P, and Gao, Allen C. "Resistance Mechanisms to Taxanes and PARP Inhibitors in Advanced Prostate Cancer." Current opinion in endocrine and metabolic research vol. 10 (2020): 16-22. doi: https://doi.org/10.1016/j.coemr.2020.02.006
Lombard AP, Gao AC. Resistance Mechanisms to Taxanes and PARP Inhibitors in Advanced Prostate Cancer. Curr Opin Endocr Metab Res. 2020 Feb;10:16-22. doi: 10.1016/j.coemr.2020.02.006. Epub 2020 Feb 19. PMID: 32258820; PMCID: PMC7111181.
Copy Download .nbib Format: NLM
Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer.

Asian journal of urology

Armstrong CM, Gao AC.
PMID: 28642838
Asian J Urol. 2016 Oct;3(4):185-194. doi: 10.1016/j.ajur.2016.08.001. Epub 2016 Aug 22.

The therapies available for prostate cancer patients whom progress from hormone-sensitive to castration resistant prostate cancer include both systemic drugs, including docetaxel and cabazitaxel, and drugs that inhibit androgen signaling such as enzalutamide and abiraterone. Unfortunately, it is estimated...

Cite
Armstrong CM, Gao AC. Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer. Asian J Urol. 2016;3(4):185-194doi: 10.1016/j.ajur.2016.08.001.
Armstrong, C. M., & Gao, A. C. (2016). Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer. Asian journal of urology, 3(4), 185-194. https://doi.org/10.1016/j.ajur.2016.08.001
Armstrong, Cameron M, and Gao, Allen C. "Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer." Asian journal of urology vol. 3,4 (2016): 185-194. doi: https://doi.org/10.1016/j.ajur.2016.08.001
Armstrong CM, Gao AC. Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer. Asian J Urol. 2016 Oct;3(4):185-194. doi: 10.1016/j.ajur.2016.08.001. Epub 2016 Aug 22. PMID: 28642838; PMCID: PMC5477778.
Copy Download .nbib Format: NLM
Current strategies for targeting the activity of androgen receptor variants.

Asian journal of urology

Armstrong CM, Gao AC.
PMID: 30775247
Asian J Urol. 2019 Jan;6(1):42-49. doi: 10.1016/j.ajur.2018.07.003. Epub 2018 Sep 29.

Current therapies for advanced prostate cancer, such as enzalutamide and abiraterone, focus on inhibiting androgen receptor (AR) activity and reducing downstream signaling pathways to inhibit tumor growth. Unfortunately, cancer cells are very adaptable and, over time, these cells develop...

Cite
Armstrong CM, Gao AC. Current strategies for targeting the activity of androgen receptor variants. Asian J Urol. 2018;6(1):42-49doi: 10.1016/j.ajur.2018.07.003.
Armstrong, C. M., & Gao, A. C. (2019). Current strategies for targeting the activity of androgen receptor variants. Asian journal of urology, 6(1), 42-49. https://doi.org/10.1016/j.ajur.2018.07.003
Armstrong, Cameron M, and Gao, Allen C. "Current strategies for targeting the activity of androgen receptor variants." Asian journal of urology vol. 6,1 (2019): 42-49. doi: https://doi.org/10.1016/j.ajur.2018.07.003
Armstrong CM, Gao AC. Current strategies for targeting the activity of androgen receptor variants. Asian J Urol. 2019 Jan;6(1):42-49. doi: 10.1016/j.ajur.2018.07.003. Epub 2018 Sep 29. PMID: 30775247; PMCID: PMC6363599.
Copy Download .nbib Format: NLM
Activation of the .

Molecular cancer therapeutics

Lombard AP, Lou W, Armstrong CM, D'Abronzo LS, Ning S, Evans CP, Gao AC.
PMID: 34326198
Mol Cancer Ther. 2021 Oct;20(10):2061-2070. doi: 10.1158/1535-7163.MCT-20-0983. Epub 2021 Jul 29.

Docetaxel and cabazitaxel-based taxane chemotherapy are critical components in the management of advanced prostate cancer. However, their efficacy is hindered due to

Cite
Lombard AP, Lou W, Armstrong CM, et al. Activation of the . Mol Cancer Ther. 2021;20(10):2061-2070doi: 10.1158/1535-7163.MCT-20-0983.
Lombard, A. P., Lou, W., Armstrong, C. M., D'Abronzo, L. S., Ning, S., Evans, C. P., & Gao, A. C. (2021). Activation of the . Molecular cancer therapeutics, 20(10), 2061-2070. https://doi.org/10.1158/1535-7163.MCT-20-0983
Lombard, Alan P, et al. "Activation of the ." Molecular cancer therapeutics vol. 20,10 (2021): 2061-2070. doi: https://doi.org/10.1158/1535-7163.MCT-20-0983
Lombard AP, Lou W, Armstrong CM, D'Abronzo LS, Ning S, Evans CP, Gao AC. Activation of the . Mol Cancer Ther. 2021 Oct;20(10):2061-2070. doi: 10.1158/1535-7163.MCT-20-0983. Epub 2021 Jul 29. PMID: 34326198; PMCID: PMC8492550.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries